ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Taipei City, TWN:

Locations recently updated

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Taipei, Taiwan and 66 other locations

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come bac...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Taipei City, Taiwan and 92 other locations

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma...

Enrolling
High-grade B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Loncastuximab Tesirine

Phase 1

ADC Therapeutics

Taipei, Taiwan and 13 other locations

Locations recently updated

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recomm...

Enrolling
Non-Hodgkin Lymphoma
Drug: CHO-H01
Drug: Lenalidomide

Phase 1, Phase 2

Cho Pharma

Taipei, Taiwan and 7 other locations

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 59 other locations

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

Enrolling
EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Taipei City, Taiwan and 93 other locations

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Taipei, Taiwan and 215 other locations

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Begins enrollment this month
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Taipei, Taiwan and 64 other locations

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: DR-0201

Phase 1

Dren Bio

Taipei, Taiwan and 15 other locations

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)

safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

Phase 2

BeiGene
BeiGene

Taipei, Taiwan and 119 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems